1527 related articles for article (PubMed ID: 30959157)
1. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
2. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.
Cabibbo G; Petta S; Barbara M; Attardo S; Bucci L; Farinati F; Giannini EG; Negrini G; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Virdone R; Marra F; Mega A; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Olivani A; Masotto A; Nardone G; Colecchia A; Persico M; Craxì A; Trevisani F; Cammà C;
J Hepatol; 2017 Jul; 67(1):65-71. PubMed ID: 28192185
[TBL] [Abstract][Full Text] [Related]
3. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma, decompensation, and mortality based on hepatitis C treatment: A prospective cohort study.
Choi GH; Jang ES; Kim YS; Lee YJ; Kim IH; Cho SB; Lee HC; Jang JW; Ki M; Choi HY; Baik D; Jeong SH
World J Gastroenterol; 2022 Aug; 28(30):4182-4200. PubMed ID: 36157119
[TBL] [Abstract][Full Text] [Related]
6. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
7. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.
Ochi H; Hiraoka A; Hirooka M; Koizumi Y; Amano M; Azemoto N; Watanabe T; Yoshida O; Tokumoto Y; Mashiba T; Yokota T; Abe M; Michitaka K; Hiasa Y; Joko K
J Gastroenterol; 2021 Jan; 56(1):90-100. PubMed ID: 33278003
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.
Chen YS; Huang KH; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Lin YP; Tsai MC
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208582
[No Abstract] [Full Text] [Related]
9. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
[TBL] [Abstract][Full Text] [Related]
10. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
11. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.
Mariño Z; Darnell A; Lens S; Sapena V; Díaz A; Belmonte E; Perelló C; Calleja JL; Varela M; Rodriguez M; Rodriguez de Lope C; Llerena S; Torras X; Gallego A; Sala M; Morillas RM; Minguez B; Llaneras J; Coll S; Carrion JA; Iñarrairaegui M; Sangro B; Vilana R; Sole M; Ayuso C; Ríos J; Forns X; Bruix J; Reig M
J Hepatol; 2019 May; 70(5):874-884. PubMed ID: 30684506
[TBL] [Abstract][Full Text] [Related]
12. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
Sangiovanni A; Alimenti E; Gattai R; Filomia R; Parente E; Valenti L; Marzi L; Pellegatta G; Borgia G; Gambato M; Terreni N; Serio I; Belli L; Oliveri F; Maimone S; Brunacci M; D'Ambrosio R; Forzenigo LV; Russo FP; Rumi M; Barone M; Fracanzani AL; Raimondo G; Giannini EG; Brunetto MR; Villa E; Biganzoli E; Colombo M; Lampertico P
J Hepatol; 2020 Sep; 73(3):593-602. PubMed ID: 32243959
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
14. Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals.
Tanaka S; Shinkawa H; Tamori A; Takemura S; Takahashi S; Amano R; Kimura K; Ohira G; Kawada N; Kubo S
J Surg Oncol; 2020 Dec; 122(8):1543-1552. PubMed ID: 32856301
[TBL] [Abstract][Full Text] [Related]
15. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study.
Cabibbo G; Petta S; Calvaruso V; Cacciola I; Cannavò MR; Madonia S; Distefano M; Larocca L; Prestileo T; Tinè F; Bertino G; Giannitrapani L; Benanti F; Licata A; Scalisi I; Mazzola G; Cartabellotta F; Alessi N; Barbàra M; Russello M; Scifo G; Squadrito G; Raimondo G; Craxì A; Di Marco V; Cammà C;
Aliment Pharmacol Ther; 2017 Oct; 46(7):688-695. PubMed ID: 28791711
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
17. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.
Singal AG; Rich NE; Mehta N; Branch AD; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Ioannou GN; Huang A; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Kagan S; Gopal P; Wong R; Parikh ND; Murphy CC
Gastroenterology; 2019 Nov; 157(5):1253-1263.e2. PubMed ID: 31374215
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
Ohki T; Sato K; Kondo M; Goto E; Sato T; Kondo Y; Akamatsu M; Sato S; Yoshida H; Koike Y; Obi S
J Viral Hepat; 2021 Nov; 28(11):1597-1603. PubMed ID: 34312954
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
20. Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma.
Kamp WM; Sellers CM; Stein S; Lim JK; Kim HS
J Vasc Interv Radiol; 2020 Jun; 31(6):953-960. PubMed ID: 32376182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]